首页> 外国专利> Use of dabigatran etexilate, dabigatran, (N - N - 2 - 2 - pyridyl amide acid - etoxicarboniletil) of 1 - methyl - 2 - 4 - (N - hidroxiamidino) benzimidazole fenilaminoetil - 5 - il - carboxylic acid, melagatran, ximelagatran,Hirudin, hirulog and Argatroban In Treatment of cerebral infarction, myocardial infarction, thrombosis, pulmonary embolism, among others.

Use of dabigatran etexilate, dabigatran, (N - N - 2 - 2 - pyridyl amide acid - etoxicarboniletil) of 1 - methyl - 2 - 4 - (N - hidroxiamidino) benzimidazole fenilaminoetil - 5 - il - carboxylic acid, melagatran, ximelagatran,Hirudin, hirulog and Argatroban In Treatment of cerebral infarction, myocardial infarction, thrombosis, pulmonary embolism, among others.

机译:达比加群酯的使用,达比加群,(N-N-2-2-吡啶基酰胺酸-etoxicarboniletiltil)的1-甲基-2-[4-(N-Hidroxiamidino)苯并咪唑苯甲胺基]-5-il-羧酸,melagatran, ximelagatran,Hirudin,hirulog和Argatroban用于治疗脑梗死,心肌梗塞,血栓形成,肺栓塞等。

摘要

Use of compound specific Direct Thrombin Inhibitors for prophylaxis and / or treatment of a Selected disease of cerebral InfarctCardiovascular Disorders and pulmonary infarction among others.
机译:化合物特异性直接凝血酶抑制剂在预防和/或治疗脑梗塞的选定疾病,心血管疾病和肺梗塞等疾病中的用途。

著录项

  • 公开/公告号CL2007002068A1

    专利类型

  • 公开/公告日2008-01-18

    原文格式PDF

  • 申请/专利权人 BOEHRINGER INGELHEIM INTERNATIONAL GMBH;

    申请/专利号CL20070002068

  • 申请日2007-07-13

  • 分类号A61K31/397;A61K31/4439;A61K31/4709;A61K38/58;A61P15/10;A61P7/02;A61P9/04;A61P9/06;A61P9/10;A61P9/14;

  • 国家 CL

  • 入库时间 2022-08-21 20:08:33

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号